Cancer patients with rheum side effects respond well to usual therapy


Rheumatological immune-related adverse events (irAEs) related to checkpoint inhibitor use in cancer patients appear to respond well to the usual rheumatology therapies, according to data presented at the ACR 2017 meeting in San Diego. A small retrospective study from the Royal Melbourne Hospital and Peter MacCallum Cancer Centre found 13 of 18 patients treated with ...


Already a member? Login to keep reading


OR
© 2017 the limbic